Novavax, Inc. (NVAX) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Novavax (NVAX) by buying shares or fractional shares at any major US broker, through a biotech or vaccine-focused ETF that holds it, or as one holding in a thematic basket. Novavax is a vaccine company built around a protein-based platform and its Matrix-M adjuvant, and by 2026 it has pivoted from selling its own COVID vaccine directly to a partnership and licensing model. Its lead product Nuvaxovid is now commercialized largely through Sanofi, while Matrix-M is being licensed to partners including Pfizer for use across other vaccines. The single biggest thing to understand is that this is a smaller-cap biotech transitioning toward royalties and milestone payments, so the thesis rests on partner execution and deal milestones rather than on a large in-house product business.
NVAX stock price
As of 2026-07-14, Novavax, Inc. (NVAX) last closed at $8.66, up 24.3% over the past year. Over the past 52 weeks it has traded between $6.22 and $11.19.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Novavax, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Novavax, Inc. (NVAX) do?
Novavax is a biotechnology company known for protein-based vaccines and its proprietary Matrix-M adjuvant, a saponin-based compound that boosts the immune response to a vaccine. Its best-known product is Nuvaxovid, a protein-based COVID-19 vaccine that offered an alternative to the mRNA shots from Pfizer and Moderna. After years of manufacturing and cash-burn struggles, Novavax restructured its strategy: rather than carrying the full cost of producing and marketing vaccines itself, it now leans on partners to commercialize its products and licenses its adjuvant technology to others.
The centerpiece of that shift is a partnership with Sanofi, under which Sanofi took on much of the commercialization of Nuvaxovid and gained rights to use Matrix-M in its own vaccines, leaving Novavax eligible for substantial future milestone payments and royalties. In January 2026 Novavax signed a separate license with Pfizer for Matrix-M, receiving an upfront payment and the potential for further development and sales milestones. In Q1 2026 the company reported revenue of roughly $140 million, well above expectations, driven largely by partnership and licensing income, and it guided to full-year 2026 revenue in a range of roughly $230 million to $270 million. The model is increasingly about royalties, milestones, and adjuvant licensing across infectious disease and other areas, rather than a large direct-sales vaccine franchise.
What's driving Novavax, Inc. (NVAX)?
1. Sanofi partnership and milestones
The Sanofi relationship is the anchor of the new Novavax. Sanofi commercializes Nuvaxovid and can use Matrix-M in its own vaccines, and Novavax remains eligible for large additional milestone payments tied to Nuvaxovid and a COVID-influenza combination program. Positive clinical data comparing Nuvaxovid favorably to an mRNA vaccine on tolerability supports the partnership. How reliably these milestones convert into cash is central to the story.
2. Matrix-M adjuvant licensing
Matrix-M is Novavax's most valuable asset, and the strategy is to license it broadly. The January 2026 Pfizer agreement, with an upfront payment and up to hundreds of millions in potential milestones, is a template. Each additional partner that adopts Matrix-M across infectious disease or other vaccine programs adds a potential royalty stream without Novavax bearing full development cost, though deals take time to sign and mature.
3. Shift to a capital-light royalty model
By stepping back from large-scale in-house manufacturing and marketing, Novavax has aimed to cut its cash burn and stabilize its balance sheet. A leaner, royalty-and-milestone model can be less capital intensive than running a full commercial vaccine operation. The 2026 guidance reflects a business built more on licensing and partnership revenue than on direct product sales, which changes its risk and margin profile.
4. Pipeline and platform optionality
Beyond COVID, Novavax has explored applying its protein-based platform and Matrix-M to other targets, including combination and seasonal respiratory vaccines. The platform gives optionality if partners advance new programs. This is early-stage and uncertain, but it means the company is not solely a single-product story, and successful data readouts by partners could open additional licensing opportunities over time.
What are the risks to Novavax, Inc. (NVAX)?
Novavax remains a speculative small-cap biotech with meaningful risks. Its revenue increasingly depends on partners such as Sanofi and Pfizer, so milestone timing, partner decisions, and program prioritization are largely outside its control. Demand for COVID vaccines has fallen sharply from pandemic peaks, and seasonal booster uptake is uncertain, which pressures the underlying Nuvaxovid franchise. The company has a history of cash burn, dilution, manufacturing setbacks, and volatile results, and its stock can swing sharply on trial data, regulatory news, and deal announcements. Guidance ranges are wide and depend on licensing income that may not recur. Competition in vaccines and adjuvants is intense, and there is no guarantee that new Matrix-M partnerships will materialize on favorable terms.
How is Novavax, Inc. (NVAX) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Novavax, Inc.'s investor relations page or your broker.
- Revenue (2026 guidance): ~$230 million to $270 million range guided for full-year 2026
- Q1 2026 revenue: ~$140 million, above expectations, driven largely by partnership and licensing income
- Revenue mix: Weighted toward licensing, royalties, and milestones rather than direct product sales
- Market cap: Small-cap (roughly a low single-digit billion; verify live)
- Profitability: Historically loss-making with a cash-burn history; results are lumpy and milestone-driven
- Balance sheet: Restructured toward a leaner model to reduce burn; cash position should be checked live
These figures are approximate and tied to the asOf date; verify live numbers before acting. Novavax's revenue is increasingly lumpy because it depends on one-time milestone and licensing payments that may not repeat quarter to quarter, so a single strong quarter can overstate the run-rate. Traditional earnings multiples are of limited use for a transitioning biotech like this, where the value depends on future partner milestones and royalties rather than steady product sales.
Who competes with Novavax, Inc. (NVAX)?
COVID and mRNA vaccine makers
Pfizer with BioNTech, and Moderna, dominate the COVID vaccine market with mRNA platforms. Novavax's protein-based Nuvaxovid competes as an alternative option, but overall COVID vaccine demand has fallen from pandemic highs, and these larger, better-capitalized rivals set the pace on pricing and distribution.
Large diversified vaccine companies
Sanofi, GSK, and Merck run broad vaccine franchises across many diseases and have their own adjuvant and platform technologies. Sanofi is now both a key Novavax partner and a giant in the field, which highlights how much smaller Novavax is relative to the incumbents it works alongside and competes with.
Adjuvant and platform technology players
Matrix-M competes with other adjuvant systems, including GSK's AS01, and with alternative vaccine platforms from various biotechs. Novavax's licensing thesis depends on partners choosing Matrix-M over these competing technologies, so the competitive landscape for adjuvants directly affects its future royalty potential.
How to invest in Novavax, Inc. (NVAX)
There are three common ways to get NVAX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NVAX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where NVAX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Novavax, Inc. (NVAX)
Novavax is a speculative small-cap biotech shifting from a direct vaccine seller to a partnership-and-royalty model anchored by Sanofi and its Matrix-M adjuvant. Upside depends on milestone payments and new licensing deals landing, while the business remains small, volatile, and dependent on partners.
Build a basket around NVAX with Walnut
Use Novavax, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NVAX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that the pivot to a partnership-and-royalty model with Sanofi and Pfizer could turn Matrix-M and Nuvaxovid into steady milestone and royalty income at lower cost. The bear case is that Novavax is a small, volatile biotech whose revenue is lumpy and dependent on partners, with falling COVID vaccine demand and a history of cash burn and dilution. Weigh both against your portfolio.
What does Novavax actually do?
+
Novavax develops protein-based vaccines and owns the Matrix-M adjuvant, a compound that strengthens the immune response to a vaccine. Its main product is Nuvaxovid, a protein-based COVID-19 vaccine. By 2026 it has shifted toward commercializing products through partners and licensing Matrix-M to companies like Pfizer, earning upfront payments, milestones, and royalties rather than relying only on direct sales.
What is the Sanofi partnership about?
+
Under the partnership, Sanofi took on much of the commercialization of Nuvaxovid and gained rights to use Matrix-M in its own vaccines. In exchange, Novavax became eligible for large additional milestone payments, including amounts tied to Nuvaxovid and a COVID-influenza combination program, plus potential royalties. It is the anchor of Novavax's shift to a lighter, partner-driven business model.
Why is Novavax stock so volatile?
+
Novavax is a smaller-cap biotech whose results depend heavily on clinical data, regulatory decisions, partner milestones, and licensing deals, all of which can arrive unpredictably. It also has a history of cash burn and share dilution. Because a single milestone payment or trial readout can move the outlook significantly, the stock can swing sharply on news, which makes it more speculative than a large, diversified pharma name.
Does Novavax pay a dividend?
+
No. Novavax does not pay a dividend. Like most clinical-stage and transitioning biotech companies, it directs its resources toward its platform, partnerships, and operations rather than returning cash to shareholders. Investors in NVAX are relying entirely on potential share-price appreciation, not income, and should not expect a payout. Always confirm the latest policy before assuming anything.
What is Matrix-M and why does it matter?
+
Matrix-M is Novavax's proprietary adjuvant, a saponin-based compound that boosts the immune response generated by a vaccine. It is arguably the company's most valuable asset because it can be licensed to other vaccine makers across many diseases. Novavax's 2026 strategy leans on licensing Matrix-M to partners such as Pfizer, creating potential milestone and royalty income without Novavax funding every program itself.
How can I get exposure to Novavax through an ETF?
+
NVAX appears in various biotechnology and broad healthcare ETFs, where it sits among many drug and vaccine developers. ETF exposure spreads single-stock risk across dozens of holdings but dilutes how much any Novavax move affects you, and in a large fund its weighting may be small. Always check a fund's holdings and weighting before assuming meaningful exposure to Novavax specifically.
Is Novavax profitable?
+
Novavax has a history of operating losses and cash burn, and its revenue is lumpy because it depends heavily on one-time milestone and licensing payments. A strong quarter, like Q1 2026, can reflect a large upfront payment rather than a steady run-rate. Whether the restructured, partner-driven model produces durable profitability over time is one of the key open questions for investors. Verify the latest financials before acting.
What are the main risks of investing in NVAX?
+
The central risks are dependence on partners like Sanofi and Pfizer for milestone and royalty income, falling and uncertain COVID vaccine demand, a history of cash burn and dilution, and lumpy, hard-to-predict revenue. The stock is volatile and reacts sharply to trial data, regulatory news, and deal announcements. Competition in vaccines and adjuvants is intense, and new Matrix-M licensing deals are not guaranteed to arrive on favorable terms.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Novavax, Inc.'s investor relations page or your broker before making investment decisions.